The CRO industry extreme pointed 2...

The CRO industry extreme pointed 2004 on a roll, and it contemplates like the good times will continue well into 2005

2004 was especially sinewy for companies providing early exhibition services, including preclinical and phase 1 research, bioanalytical and analytical chemistry, and clinical trial materials, manufacturing, and packaging. most numerous CROs saw revenue gains of 20 % or more in their early progression in a continuously ascending gradation services, with preclinical, phase 1 and analytical chemistry especially hardy The only weak spot was phase 1 studies in Europe where the strange Clinical Trials Directive (CTD) appears to ...